Advertisement
Research Article Free access | 10.1172/JCI113560
Harvard Medical School, New England Regional Primate Research Center, Southborough, Massachusetts 01772.
Find articles by Reimann, K. in: JCI | PubMed | Google Scholar
Harvard Medical School, New England Regional Primate Research Center, Southborough, Massachusetts 01772.
Find articles by Goldmacher, V. in: JCI | PubMed | Google Scholar
Harvard Medical School, New England Regional Primate Research Center, Southborough, Massachusetts 01772.
Find articles by Lambert, J. in: JCI | PubMed | Google Scholar
Harvard Medical School, New England Regional Primate Research Center, Southborough, Massachusetts 01772.
Find articles by Chalifoux, L. in: JCI | PubMed | Google Scholar
Harvard Medical School, New England Regional Primate Research Center, Southborough, Massachusetts 01772.
Find articles by Cook, S. in: JCI | PubMed | Google Scholar
Harvard Medical School, New England Regional Primate Research Center, Southborough, Massachusetts 01772.
Find articles by Schlossman, S. in: JCI | PubMed | Google Scholar
Harvard Medical School, New England Regional Primate Research Center, Southborough, Massachusetts 01772.
Find articles by Letvin, N. in: JCI | PubMed | Google Scholar
Published July 1, 1988 - More info
The cytotoxic effect of a lymphocyte-specific immunotoxin formed by disulfide conjugation of an anti-T11 monoclonal antibody with the ribosome-inactivating protein gelonin was assessed in vitro on peripheral blood T cells and in vivo on splenic and lymph node T cells of macaque monkeys. This immunotoxin was cytotoxic to proliferating peripheral blood T cells in vitro as measured by both direct and indirect assays. Two sequential intravenous infusions into macaque monkeys achieved plasma concentrations of immunotoxin far in excess of those shown to be cytotoxic for cultured T cells and coated all T cells in lymph nodes and spleen with intact immunotoxin for four days. However, the cytotoxic effect of the immunotoxin on T cells in vivo was considerably less than that predicted by the in vitro studies. Further experiments suggested that the state of activation of the targeted T cell population in vivo, or the appearance of anti-immunotoxin antibodies, which occurred in all infused monkeys, might attenuate immunotoxin-mediated cell killing in vivo. These studies illustrate the significant differences between the action of immunotoxin conjugates in vitro, and those seen when these conjugates are utilized as therapeutic agents in vivo.
Images.